NCT06440954 Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases Status RECRUITING Phase PHASE2
NCT06436885 An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer Status RECRUITING Phase EARLY_PHASE1
NCT06422403 A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers Status RECRUITING Phase PHASE2
NCT06422143 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] Status RECRUITING Phase PHASE3
NCT06406608 Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer Status RECRUITING Phase NA
NCT06403735 A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT06403111 FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC Status RECRUITING Phase PHASE2
NCT06394674 High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib Status RECRUITING Phase PHASE2
NCT06388031 ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI Status RECRUITING Phase PHASE2
NCT06382129 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06379087 Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC Status RECRUITING Phase PHASE2
NCT06370416 the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib Status ENROLLING_BY_INVITATION Phase PHASE2
NCT06363734 Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial Status RECRUITING Phase PHASE2
NCT06358222 Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan Status RECRUITING Phase N/A
NCT06357533 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations Status RECRUITING Phase PHASE3
NCT06355609 Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW Status RECRUITING Phase PHASE2
NCT06352008 To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer Status RECRUITING Phase PHASE2